Preventing GVHD after stem cell transplant with three drugs
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a three-drug combination (cyclophosphamide, tacrolimus, and ruxolitinib) to prevent graft-versus-host disease (GVHD) after a stem cell transplant. It is for people with certain blood cancers who have a matched donor and can tolerate high-dose chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older with a blood cancer like acute leukemia or MDS, and the disease is well-controlled (low blast count).
- You will receive a high-dose (myeloablative) chemotherapy regimen before transplant.
- You have a matched sibling or unrelated donor willing to donate peripheral blood stem cells.
- Your heart, kidney, lung, and liver function tests meet certain minimum levels.
- You have not had a prior stem cell transplant or taken ruxolitinib before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (vedolizumab, cyclophosphamide, and tacrolimus) to prevent graft-versus-host disease, a common complication after a donor stem cell transplant. It is for people with certain blood cancers who are getting a reduced-intensity transplant.
This trial tests adding ruxolitinib to standard drugs (tacrolimus and methotrexate) to prevent graft-versus-host disease in children and young adults undergoing a stem cell transplant for acute leukemia or myelodysplastic syndrome. The goal is to lower the risk of GVHD and improve transplant outcomes.
This trial tests two different combinations of medicines to prevent graft-versus-host disease (when donor cells attack your body) after a stem cell transplant. The goal is to see which approach works better for people with certain blood cancers or lymphomas.
This trial tests a combination of three drugs (PTCy, bortezomib, and sitagliptin) after a stem cell transplant to help prevent graft-versus-host disease (GVHD). It is for people with certain blood cancers who are getting a reduced-intensity (gentler) transplant.
This trial tests a combination of four medicines (cyclophosphamide, abatacept, vedolizumab, and ruxolitinib) to prevent graft-versus-host disease (GVHD) after a stem cell transplant for children and young adults with certain blood cancers. The goal is to see if this approach reduces the risk of GVHD, a serious complication where donor cells attack the body.
This trial tests a new way to prevent graft-versus-host disease (GvHD), a common complication after a stem cell transplant. It is for people with certain blood cancers who are getting a stem cell transplant from a half-matched family member or unrelated donor.
Hear when a new Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.